As Mexican demand for thematic investment
solutions grows, First Trust expands its offerings.
First Trust Advisors L.P. (“First Trust”), a global ETF provider
and asset manager, announced today that it has cross-listed two
additional UCITS ETFs on the Mexican stock exchange, the Bolsa
Mexicana de Valores and/or the Bolsa Institucional de Valores. As
many institutional investors seek to invest within Mexico, First
Trust is pleased to expand its offerings of UCITS funds. First
Trust entered the Mexican market beginning in 2011. The additional
listing brings the total number of Mexican listed First Trust UCITS
ETFs to 13.
Newly Approved
First Trust NYSE Arca Biotechnology UCITS ETF (FBTU LN) First
Trust Nasdaq Cybersecurity UCITS ETF (CIBR LN)
“To complement our growing lineup of UCITS available to Mexico
investors, we are pleased to cross list two of our most desired and
successful thematic strategies as UCITS ETFs,” said April Reppy
Suydam, Head of Latin America Distribution, First Trust.
For more information about First Trust, please contact Ryan
Issakainen at (630) 765-8689 or RIssakainen@FTAdvisors.com.
About First Trust
First Trust, a federally registered investment advisor, and its
affiliate First Trust Portfolios L.P. (“FTP”), a FINRA registered
broker-dealer, are privately held companies that provide a variety
of investment services. First Trust is the investment advisor to
exchange-traded funds, closed-end funds, mutual funds, separate
managed accounts and provides supervisory services to FTP sponsored
unit investment trusts. First Trust’s assets under management were
approximately $145.753 billion as of July 31, 2020. This includes
the supervisory services First Trust provides to FTP sponsored unit
investment trusts, which are unmanaged. FTP is a sponsor of unit
investment trusts and distributor of mutual fund shares and
exchange-traded fund creation units. First Trust is based in
Wheaton, Illinois. For more information, visit
http://www.ftportfolios.com.
You should consider a fund’s investment objectives, risks,
and charges and expenses carefully before investing. Contact First
Trust Portfolios L.P. at 1-800-621-1675 to obtain a prospectus
which contains this and other information about a fund. The
prospectus should be read carefully before investing.
Risks
The funds’ shares may change in value and may go down as well
as up. You could lose money by investing in the funds. You may not
get back all of the money you invest.
The funds are subject to Market Risk, which means that shares of
the funds may fall in value due to market fluctuations caused by
factors such as economic, political, regulatory or market
developments, changes in interest rates and perceived trends in
securities prices.
Biotechnology and pharmaceutical companies are subject to
changing government regulation which could have a negative effect
on the price, profitability and availability of their products and
services. Biotechnology and pharmaceutical companies face
increasing competition from generic drugs, termination of their
patent protection and technological advances which render their
products or services obsolete. The research and development costs
required to bring a drug to market are substantial and may include
a lengthy review by the government, with no guarantee that the
product will ever be brought to market or show a profit. Many of
these companies may not offer certain drugs or products for several
years, and as a result, may have significant losses of revenue and
earnings.
Information technology companies and cybersecurity companies are
generally subject to the risks of rapidly changing technologies,
short product life cycles, fierce competition, aggressive pricing
and reduced profit margins, loss of patent, copyright and trademark
protections, cyclical market patterns, evolving industry standards
and frequent new product introductions. Cybersecurity companies may
also be smaller and less experienced companies, with limited
product lines, markets, qualified personnel or financial
resources.
There may be tracking difference between the funds and the
underlying index due to the impact of the annual fund management
fees. Therefore, the funds’ returns may not match the returns of
the index.
The outbreak of the respiratory disease designated as COVID-19
in December 2019 has caused significant volatility and declines in
global financial markets, which have caused losses for investors.
The COVID-19 pandemic may last for an extended period of time and
will continue to impact the economy for the foreseeable future.
The funds’ Net Asset Value (NAV) is likely to have high
volatility due to the portfolio composition and/or the index
replication technique. As such, potential investors should be aware
that the funds’ shares may change in value, and may do so in a
volatile fashion; potential investors could lose money by investing
in the funds.
Neither First Trust Global Portfolios Limited (“FTGP”) nor any
of its affiliates, guarantees the performance or the future returns
of the funds.
For more details relating to risks of investing in the funds,
please refer to the “Risk Factors” section of the fund’s
prospectus.
Important Information
This information is not intended for distribution to, or use by,
any U.S. investors and does not constitute an offer or solicitation
of securities for sale in the United States. The shares of the Fund
have not been registered under the U.S. Securities Act of 1933, as
amended, and the Fund is not registered under the U.S. Investment
Company Act of 1940, as amended.
The First Trust NYSE Arca Biotechnology UCITS ETF and the First
Trust Nasdaq Cybersecurity UCITS ETF (the “funds”) are open-ended
sub-funds of the First Trust Global Funds PLC, an umbrella UCITS
fund with segregated liability between sub-funds, incorporated with
limited liability as an investment company with variable capital
under the laws of Ireland with UCITS registered number 514357.
Shares of the funds are offered solely to non-US persons pursuant
to the terms and conditions of the Funds’ prospectus. The Funds’
prospectus contain important information about the funds and should
be read carefully before investing. Please call 1-800-621-9533 to
obtain a copy of the prospectus and the Key Investor Information
Document. Prospective investors should consult their financial and
tax advisor before making an investment in the Funds in order to
independently assess the merits of such an investment.
This document does not constitute investment advice or an offer
or solicitation to sell or a solicitation of an offer to buy any
shares of any investment fund (nor shall any such shares be offered
or sold to any person) in any jurisdiction in which an offer,
solicitation, purchase or sale would be unlawful under the
securities law of that jurisdiction. It is the responsibility of
any prospective investor to inform themselves of and to observe all
applicable laws and regulations of any relevant jurisdictions.
Prospective investors should inform themselves as to the legal
requirements and tax consequences within the countries of their
citizenship, residence, domicile and place of business with respect
to the acquisition, holding or disposal of shares, and any foreign
exchange restrictions that may be relevant thereto.
In no event shall First Trust Advisors L.P. or any of its
affiliates have any liability for direct, indirect, special,
incidental, punitive or consequential (including, without
limitation, lost profits) losses or any damages resulting from the
use of this material.
The funds list and principally trade their shares on the London
Stock Exchange, Bolsa Mexicana de Valores and/or the Bolsa
Institucional de Valores.
The funds’ return may not match the return of the NYSE Arca
Biotechnology Index℠ or the Nasdaq CTA Cybersecurity Index℠.
Securities held by the funds will generally not be bought or sold
in response to market fluctuations.
Investors buying or selling fund shares on the secondary market
may incur customary brokerage commissions. Market prices may differ
to some degree from the net asset value of the shares. Investors
who sell fund shares may receive less than the share's net asset
value. Shares may be sold throughout the day on the exchange
through any brokerage account. However, unlike mutual funds, shares
may only be redeemed directly from the fund by authorized
participants, in very large creation/redemption units. If the
funds’ authorized participants are unable to proceed with
creation/redemption orders and no other authorized participant is
able to step forward to create or redeem, fund shares may trade at
a discount to the funds’ net asset value and possibly face
delisting.
The information presented is not intended to constitute an
investment recommendation for, or advice to, any specific person.
Nor does the document implicitly or explicitly recommend or suggest
an investment strategy, reach conclusions in relation to an
investment strategy for the reader or provide an opinion as to the
present or future value or price of any fund. First Trust has no
knowledge of and has not been provided any information regarding
any investor. Financial professionals must determine whether
particular investments are appropriate for their clients.
The views and opinions expressed are for informational
purposes only. This material is not intended to be relied upon as
investment advice or recommendations, does not constitute a
solicitation to buy or sell securities (in any jurisdiction to any
person to whom it is not lawful to make such an offer) and should
not be considered specific legal, investment or tax advice.
For Investors in Mexico:
The funds have been cross-listed on the Bolsa Mexicana de
Valores and/or the Bolsa Institucional de Valores.
Investors should review all relevant offering materials,
including all applicable risk factors, and should consult with
financial and tax advisors relating to tax and other consequences
of investing in a particular security prior to making an
investment. None of the securities herein have been registered with
the National Securities Registry (Registro Nacional de Valores)
maintained by the Mexican National Banking and Securities
Commission (Comisión Nacional Bancaria y de Valores). Securities
not cross-listed on the Bolsa Mexicana de Valores nor registered
with the National Securities Registry (Registro Nacional de
Valores) may not be offered or sold publicly or otherwise be the
subject of brokerage activities in Mexico, except pursuant to the
private placement exemption set forth in article 8 of the
Securities Market Law (Ley del Mercado de Valores), to
institutional and qualified investors, as defined under Mexican law
and rules thereunder.
The cross-listing of the securities identified herein does not
constitute or imply a certification as to the investment quality of
such securities or the accuracy or completeness of the information
included in all offering materials. The offering materials are
solely First Trust’s responsibility and have not been reviewed or
authorized by the CNBV or the BMV and may not be publicly offered
or distributed in Mexico. In making an investment decision, all
investors, including any Mexican investor, must rely on their own
examination of the relevant securities and the marketing
materials.
Nasdaq® and Nasdaq CTA Cybersecurity Index℠ are registered
trademarks and service marks of Nasdaq, Inc. (together with its
affiliates hereinafter referred to as the “Corporations”) and are
licensed for use by First Trust. The Fund has not been passed on by
the Corporations as to its legality or suitability. The Fund is not
issued, endorsed, sold or promoted by the Corporations. THE
CORPORATIONS MAKE NO WARRANTIES AND BEAR NO LIABILITY WITH RESPECT
TO THE FUND.
NYSE and NYSE Arca Biotechnology Index℠ (“Index”) are
service/trademarks of ICE Data Indices, LLC or its affiliates
(“IDI”) and have been licensed for use by First Trust in connection
with the Fund. The Fund is not sponsored, endorsed, sold or
promoted by IDI and IDI makes no representations or warranties
regarding the advisability of investing in the Fund or as to the
result to be obtained by any person from use of the Index in
connection with the trading of the Fund. IDI and its third party
suppliers accept no liability in connection with use of the index
or the Fund. See the prospectus for a full copy of the
disclaimer.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200904005509/en/
Ryan Issakainen First Trust (630) 765-8689
RIssakainen@FTAdvisors.com
First Trust ETF II First... (NASDAQ:CIBR)
過去 株価チャート
から 10 2024 まで 11 2024
First Trust ETF II First... (NASDAQ:CIBR)
過去 株価チャート
から 11 2023 まで 11 2024
